Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: Multicenter comparative phase 3 study

American Journal of Roentgenology

Volumn 190, Issue 1, 2008, Pages 179-186

  Bosch, Enrique ^a   Kreitner, Karl Friedrich ^b   Peirano, Mario Fava ^c   Thurner, Siegfried ^d   Shamsi, Kohkan ^e,f   Parsons Jr , Edward C ^g  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSITY OF VIENNA   (Austria)

^e BAYER CORPORATION   (United States)

^f Symbiotic Pharma Research   (United States)

^g Epix Pharmaceuticals   (United States)

Author keywords

Angiography; Arteries; Contrast media; MR angiography; Pedal artery; Peripheral arterial disease; Vascular studies

Indexed keywords

GADOFOSVESET;

ACCURACY; ADULT; AGED; ARTERY DISEASE; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FEELING COLD; FEMALE; HUMAN; HYPOGLYCEMIA; LEUKOCYTE COUNT; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; PARESTHESIA; PEDAL ARTERY DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STENOSIS; TIME OF FLIGHT MASS SPECTROMETRY; VASODILATATION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGRAPHY, DIGITAL SUBTRACTION; CONTRAST MEDIA; FEMALE; FOOT; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PERIPHERAL VASCULAR DISEASES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 37549008767     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2445     Document Type: Article

References (22)

1. Alson MD, Lang EV, Kaufman JA. Pedal arterial imaging. J Vasc Interv Radiol 1997; 8:9-18
2. Chomel S, Douek P, Moulin P, Vaudoux M, Marchand B. Contrast-enhanced MR angiography of the foot: anatomy and clinical application in patients with diabetes. AJR 2004; 182:1435-1442
3. Sharafuddin MJ, Stolpen AH, Sun S, et al. High-resolution multiphase contrast-enhanced three-dimensional MR angiography compared with two-dimensional time-of-flight MR angiography for the identification of pedal vessels. J Vasc Interv Radiol 2002; 13:695-702
4. Tongdee R, Narra VR, McNeal G, et al. Hybrid peripheral 3D contrast-enhanced MR angiography of calf and foot vasculature. AJR 2006; 186:1746-1753
5. Schmitt R, Coblenz G, Cherevatyy O, et al. Comprehensive MR angiography of the lower limbs: a hybrid dual-bolus approach including the pedal arteries. Eur Radiol 2005; 15:2513-2524
6. Leiner T, Nijenhuis RJ, Maki JH, Lemaire E, Hoogeveen R, van Engelshoven JM. Use of a three-station phased array coil to improve peripheral contrast-enhanced magnetic resonance angiography. J Magn Reson Imaging 2004; 20:417-425
7. Dorweiler B, Neufang A, Kreitner KF, Schmiedt W, Oelert H. Magnetic resonance angiography unmasks reliable target vessels for pedal bypass grafting in patients with diabetes mellitus. J Vasc Surg 2002; 35:766-772
8. Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrast-enhanced three-dimensional MR angiography with conventional digital subtraction angiography. AJR 2000; 174:171-179
9. Goyen M, Edelman M, Perreault P, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 2005; 236:825-833
10. Perreault P, Edelman MA, Baum RA, et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology 2003; 229:811-820
11. Rapp JH, Wolff SD, Quinn SF, et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography - multicenter comparative phase III study. Radiology 2005; 236:71-78
12. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 2002; 124:3152-3162
13. Parmelee DJ, Walovitch RC, Ouellet HS, Lauffer RB. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol 1997; 32:741-747
14. Bluemke DA, Stillman AE, Bis KG, et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology 2001; 219:114-122
15. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998; 207:539-544
16. Swets JA, Pickett RM. Evaluation of diagnostic Systems: methods from signal detection theory. New York, NY: Academic Press, 1982
17. Eliasziw M, Donner A. Application of the McNemar test to non-independent matched pair data. Stat Med 1991; 10:1981-1991
18. Pipe JG. Limits of time-of-flight magnetic resonance angiography. Top Magn Reson Imaging 2001; 12:163-174
19. Baum RA, Rutter CM, Sunshine JH, et al. Multi-center trial to evaluate vascular magnetic resonance angiography of the lower extremity. American College of Radiology Rapid Technology Assessment Group. JAMA 1995; 274:875-880
20. Unger EC, Schilling JD, Awad AN, et al. MR angiography of the foot and ankle. J Magn Reson Imaging 1995; 5:1-5
21. Lei T, Udupa JK, Odhner D, Nyul LG, Saha PK. 3DVIEWNIX-AVS: a software package for the separate visualization of arteries and veins in CE-MRA images. Comput Med Imaging Graph 2003; 27:351-362
22. Lei T, Udupa JK, Saha PK, et al. 3D MRA visualization and artery-vein separation using blood-pool contrast agent MS-325. Acad Radiol 2002; 9[suppl 1]:S127-S133